Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5491-5500 Newer>

Pharmaceutical Executive March 1, 2009 Walter Armstrong	Attack of the Monster Merger Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary.
Pharmaceutical Executive March 1, 2009 Steve Mapes	The End of Quid Pro Quo Exhibitor alert: Tchotchke entitlement is out, information immersion is in.
Pharmaceutical Executive March 1, 2009 Patrick Clinton	Against Gravity The worst thing about working for most corporations is the inevitable downward pull they exert even on the best of us. That's why it's always sad to lose a company that learned to fight back.
Pharmaceutical Executive March 1, 2009 Jill Wechsler	Through the Looking Glass Pharma relations with researchers are critical for developing new technology, and reformers will discourage inappropriate relationships by making any links to pharmaceutical marketing known to all.
The Motley Fool March 11, 2009 Brian Orelli	Another Test of Trust Drug companies and patients get hurt when published data might not be reliable.
The Motley Fool March 10, 2009 Brian Orelli	So Much Potential, So Little Growth In its quest to become the Johnson & Johnson of China, this purveyor of traditional Chinese medicine has been growing through acquisitions, but has paid for them through dilutive stock offerings.
The Motley Fool March 10, 2009 Devon Rackle	Almost Family: Results, Shmesults Cuts in Obama's budget proposal overshadow an otherwise solid quarter for the home health care company.
HBS Working Knowledge March 9, 2009 Christensen, Grossman & Hwang	How to Revive Health-Care Innovation Simple solutions to complex problems lead to breakthroughs in industries from retailing to personal computers to printing. So let's try health care, too.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool March 6, 2009 Brian Orelli	For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations.
<Older 5491-5500 Newer> Return to current articles.